Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa
Go back to Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa| (NASDAQ: OCGN) | Delayed: 1.03 +0.01 (0.98%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.02 | 52 Week High | $ | |||
| Open | $1.03 | 52 Week Low | $ | |||
| Day High | $1.05 | P/E | N/A | |||
| Day Low | $1.00 | EPS | $ | |||
| Volume | 4,836,469 | |||||
